Benzinga·2026-01-02 12:22Core Viewpoint - Masimo Corp. achieved a significant legal victory against Apple Inc. with a $634 million judgment, yet its underlying fundamentals indicate potential weaknesses in operational efficiency and financial health [1][6]. Fundamentals Under Pressure - Masimo's quality score has decreased to 10.43, placing it in the bottom tier of stocks for operational efficiency, indicating underperformance compared to nearly 90% of the market [2][3]. - The company's core operational metrics and historical profitability remain weak relative to industry competitors, despite the cash influx from the lawsuit [3]. Technical Indicators - The stock's momentum score is low at 8.77, reflecting weak relative strength and price movement patterns compared to other stocks [4]. - Masimo's stock is experiencing a downward trend across short, medium, and long timeframes, indicating persistent selling pressure over the past year [5]. Legal Victory - A federal jury in California ruled that Apple infringed on Masimo's blood-oxygen sensor patents, resulting in a $634 million award to Masimo, which the company views as a significant win for its innovation efforts [6]. Stock Performance - In 2025, Masimo's shares dropped by 22.85%, underperforming against the Nasdaq Composite index, which gained 20.54% during the same period [7]. - Over the last six months, the stock fell by 24.09%, closing the last trading day of 2025 at $130.06, with no change in pre-market trading [7].